Does Wegovy have an extra dose above the standard 2.4mg?

You've reached 2.4mg and wondered what comes next

It's a situation a fair number of people find themselves in: you've worked through the titration schedule, you're on 2.4mg weekly, and you're either plateauing or simply curious whether there's anywhere left to go. For a long time the answer was no. The 2.4mg dose was the top of the ladder in the UK, and that was that.

That changed at the start of 2026. In January, the MHRA authorised a 7.2mg maintenance dose for Wegovy. Practically speaking, this was initially supplied as three separate 2.4mg pens used across a single week. Then, on 14 April 2026, a purpose-built single-dose 7.2mg pen received MHRA approval, one injection, once a week, with a pre-set mechanism so the dose is fixed and the needle covers itself after use. The MHRA's announcement of the single-dose 7.2mg pen confirmed it is approved for adults with obesity, meaning a BMI of 30 or above. It does not apply to the 27–29.9 category covered by the standard Wegovy licence, and it does not extend to the cardiovascular risk reduction indication.

The titration path stays the same at the start. Treatment still begins at 0.25mg, moves through 0.5mg, 1.0mg, 1.7mg and 2.4mg at roughly four-week intervals, with 7.2mg as the new maximum. A prescriber decides whether moving to that ceiling is appropriate for you; it isn't automatic.

What the trial evidence showed for the higher dose

The reason 7.2mg cleared regulatory review is the data behind it. Across 72 weeks, participants on the 7.2mg dose achieved around 20.7% average body-weight reduction. That's a meaningful step up from the approximately 15% seen in the STEP 1 trial at 2.4mg, which was itself reported in the New England Journal of Medicine and formed the evidence base for Wegovy's original UK licence.

The 20.7% figure also matters in context: tirzepatide at its 15mg ceiling produced around 20–21% average weight loss in the SURMOUNT-1 trial, so 7.2mg semaglutide closes the distance considerably. That comparison is one reason there's been so much interest in this dose among people already on Wegovy and among those weighing up which medicine to explore. The Wegovy treatment overview covers the broader picture if you want to understand how semaglutide works before getting into the dose specifics.

One thing worth noting: clinical trial averages are exactly that. Individual responses vary. Somebody on 2.4mg achieving good weight loss with few side effects won't automatically benefit from moving higher, and a prescriber will look at the full picture before recommending a change.

How the 7.2mg dose fits alongside questions about "extra" doses in the pen

Some of the search traffic around Wegovy and extra doses comes from a different question entirely: whether there are spare or hidden doses in each individual pen, separate from the approved schedule. That's a separate topic. Each Wegovy pen contains a set number of doses at a particular strength, and there is nothing hidden beyond what the pen is designed to deliver. If you're curious about the specifics of what each pen contains, the guide to how many doses a Wegovy pen contains addresses that clearly.

Similarly, you may have come across the phrase "golden dose", again, a distinct question about whether there is an extra dose sitting unused in the pen. The Wegovy golden dose question is answered separately, but the short version is: the 7.2mg approval is a genuinely higher licensed dose, not a technique for extracting more from an existing pen. If you want to go further and understand whether there is an extra dose in the Wegovy pen, that page looks at the question in detail so you know exactly what each pen is designed to provide.

If you're thinking about what the full Wegovy dose schedule looks like from 0.25mg through to 7.2mg, that page lays it out step by step.

What this means if you're considering starting or switching

For anyone thinking about Wegovy now, the 7.2mg ceiling is simply part of the landscape. The medicine is licensed for adults with a BMI of 30 or above, or 27–29.9 alongside at least one weight-related health condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. Starting dose and any subsequent changes are prescriber decisions made on the basis of how you're responding and tolerating treatment.

The side-effect profile at 7.2mg follows the same pattern as the rest of the Wegovy schedule: gastrointestinal effects such as nausea, constipation, reflux and fatigue are the most commonly reported, and they tend to be most noticeable after starting or stepping up. The NHS semaglutide medicines page has a full, plain-English list of effects to be aware of. If you experience severe, persistent stomach pain (particularly if it reaches into your back) that needs urgent medical attention, not a wait-and-see approach.

On cost: a higher dose means a different price point. The Wegovy private pricing guide explains how costs vary by dose and what a legitimate private prescription should include. And if you want to understand whether Wegovy or an alternative might suit your situation, a consultation is the right starting point. Our prescribers review every case personally, that's not a system hand-off, it's a clinician reading your answers the same day. You can start your free consultation with nume when you're ready.